AbbVie Inc. $ABBV Shares Bought by Los Angeles Capital Management LLC

by · The Cerbat Gem

Los Angeles Capital Management LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 15.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,324,286 shares of the company’s stock after acquiring an additional 304,281 shares during the quarter. AbbVie comprises about 1.8% of Los Angeles Capital Management LLC’s investment portfolio, making the stock its 10th largest position. Los Angeles Capital Management LLC owned approximately 0.13% of AbbVie worth $538,165,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABBV. Merit Financial Group LLC raised its holdings in AbbVie by 3.1% during the 3rd quarter. Merit Financial Group LLC now owns 82,042 shares of the company’s stock worth $18,996,000 after purchasing an additional 2,461 shares during the last quarter. 3Chopt Investment Partners LLC raised its stake in shares of AbbVie by 2.9% during the third quarter. 3Chopt Investment Partners LLC now owns 15,379 shares of the company’s stock worth $3,561,000 after buying an additional 440 shares during the last quarter. Moody Lynn & Lieberson LLC lifted its holdings in AbbVie by 6.4% in the third quarter. Moody Lynn & Lieberson LLC now owns 183,462 shares of the company’s stock valued at $42,479,000 after buying an additional 11,085 shares during the period. Calamos Wealth Management LLC boosted its stake in AbbVie by 74.7% in the third quarter. Calamos Wealth Management LLC now owns 14,729 shares of the company’s stock valued at $3,410,000 after acquiring an additional 6,298 shares during the last quarter. Finally, Calamos Advisors LLC grew its holdings in AbbVie by 0.3% during the 3rd quarter. Calamos Advisors LLC now owns 450,832 shares of the company’s stock worth $104,386,000 after acquiring an additional 1,214 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ABBV shares. JPMorgan Chase & Co. increased their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Guggenheim raised their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Finally, Evercore ISI upped their price target on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average price target of $245.84.

Get Our Latest Report on AbbVie

AbbVie Stock Down 0.5%

NYSE:ABBV opened at $228.55 on Thursday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a 50-day moving average price of $226.67 and a two-hundred day moving average price of $213.37. The stock has a market cap of $403.94 billion, a price-to-earnings ratio of 173.14, a PEG ratio of 1.30 and a beta of 0.36. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the business posted $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is currently 496.97%.

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

See Also